EXAI News and Press, Exscientia Limited From 11/14/22

Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic ...

Company to host conference call and webcast on November 15, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2022, on Tuesday, November 15, 2022, before the open of U.S. markets. The ...

Fast and accurate generative AI design of novel antibodies extends Exscientia's capabilities beyond small molecules Sequencing paired human antibody data to create better AI models for antibody design Automated laboratory with proprietary hardware to enable integration...

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November: BofA Securities 2022 A.I. and Disruptive Tech Conference. Fireside chat (AI in Drug Discovery) on Wednesday, November 9, 2022, ...

Biopharma industry’s coveted prize recognizes company’s AI-driven precision medicine platform Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI...

Combines precision oncology platform with single-cell sequencing and transcriptomics with aim to select patients most likely to benefit from GTAEXS-617 therapy Confirmed and identified CDK7-specific pharmacodynamic biomarkers in cancer and immune cells Phase 1/2 clinic...

Findings support deep learning ex vivo drug screening with patient tissue as a promising tool to identify effective, individual treatments in advanced blood cancer over conventional methods Custom deep learning algorithms and single-cell analysis of >1 billion patient cells...

Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia’s People (human resources) and Places functions and build on the Company’s talent, training and employee ...

Exscientia (Nasdaq: EXAI) today announced that Company management will participate in the following investor conferences in September: Morgan Stanley Annual Global Healthcare Conference: Date: Wednesday, September 14, 2022 Time: 3:35 p.m. BST / 10:35 a.m. EST Location: New...

U.S.-listed shares of small-cap pharmatech company Exscientia ( NASDAQ: EXAI ) fell 14.1% to $9.87 in Thursday morning trading after the company reported Q2 results. EXAI after hours on Wednesday posted Q2 non-GAAP EPS of -£0.29 which missed estimates by &...